Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the Company will hold a live R&D webcast on Thursday, April 20th at 4 pm EDT to review its clinical development programs in Alzheimer’s disease …
Annovis Bio to Hold Live Webcast to Review Alzheimer’s Disease and Parkinson’s Disease Clinical Programs Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that in the last week, it has raised aggregate gross proceeds of approximately $8.7 million between its now-terminated at–the-market program and a private placement to …
Annovis Bio Raises Aggregate Gross Proceeds of Approximately $8.7 Million Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) this week announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent
Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced recent approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the recent filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: “Treatment of mental illness via …
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap Read More